OVER-MYR

Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

Coordinatore	VRIJE UNIVERSITEIT BRUSSEL    more  Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 contact info Titolo: Mr. Nome: Nik Cognome: Claesen Email: send email Telefono: 3226292210 Fax: 32226293640
Nazionalità Coordinatore	Belgium [BE]
Sito del progetto	http://www.over-myr.eu
Totale costo	3˙923˙509 €
EC contributo	2˙999˙498 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	VRIJE UNIVERSITEIT BRUSSEL  Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 contact info Titolo: Mr. Nome: Nik Cognome: Claesen Email: send email Telefono: 3226292210 Fax: 32226293640	BE (BRUSSEL)	coordinator	431˙720.00
2	UNIVERSITAETSKLINIKUM HEIDELBERG  Organization address address: IM NEUENHEIMER FELD 672 city: HEIDELBERG postcode: 69120 contact info Titolo: Mr. Nome: Thorsten Cognome: Brietz Email: send email Telefono: +49 6221 567086 Fax: +49 6221 565460	DE (HEIDELBERG)	participant	511˙680.00
3	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mr. Nome: Vincent Cognome: Boyer Email: send email Telefono: +33 4 67 63 61 46 Fax: +33 4 67 63 02 92	FR (PARIS)	participant	509˙953.00
4	Academisch Medisch Centrum bij de Universiteit van Amsterdam  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Mr. Nome: Frank J.M. Cognome: Groen Email: send email Telefono: +31 20 56 63198	NL (AMSTERDAM)	participant	324˙600.00
5	THE GARVAN INSTITUTE OF MEDICAL RESEARCH CHARITABLE INSTITUTION  Organization address address: VICTORIA STREET 384 city: SYDNEY NSW postcode: 2010 contact info Titolo: Ms. Nome: Cate Cognome: Smith Email: send email Telefono: +61 2 9295 8173 Fax: +61 2 9295 8101	AU (SYDNEY NSW)	participant	324˙600.00
6	UNIVERSITY OF SOUTHAMPTON  Organization address address: Highfield city: SOUTHAMPTON postcode: SO17 1BJ contact info Titolo: Ms. Nome: Yan Cognome: Qiao Email: send email Telefono: +44 2380593907 Fax: +44 238059 2195	UK (SOUTHAMPTON)	participant	324˙564.00
7	UNIVERSITA DEGLI STUDI DI BARI ALDO MORO  Organization address address: Piazza Umberto I 1 city: BARI postcode: 70121 contact info Titolo: Dr. Nome: Vincenzo Cognome: De Fazio Email: send email Telefono: 390805000000 Fax: 390805000000	IT (BARI)	participant	250˙800.00
8	INSERM - TRANSFERT SA  Organization address address: Rue Watt 7 city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Louis Cognome: Jammayrac Email: send email Telefono: +33 1 55030101 Fax: +33 1 55030160	FR (PARIS)	participant	176˙988.00
9	ONCODESIGN SA  Organization address address: RUE JEAN MAZEN 20 city: DIJON postcode: 21000 contact info Titolo: Dr. Nome: Jan Cognome: Hoflack Email: send email Telefono: +33 3 80 78 98 45	FR (DIJON)	participant	144˙593.00
10	CELLZOME AG  Organization address address: MEYERHOFSTRASSE 1 city: HEIDELBERG postcode: 69117 contact info Titolo: Mr. Nome: Markus Cognome: Reinhard Email: send email Telefono: 49622100000000 Fax: 49622100000000	DE (HEIDELBERG)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and cells of the bone marrow (BM) microenvironment or ‘niche’ that are critical for supporting MMC survival, proliferation and growth. Since patients repeatedly relapse after such treatments, the following mechanisms of relapse are considered and need to be investigated: i) drugs have spared specific subclones or subpopulations of MMC ii) drugs induce alterations in cells of the ‘niche’ that promote drug-resistance. OVER-MYR integrates a network of outstanding researchers from 6 EU countries with internationally recognized experience in clinics and human and animal models of MM, who will jointly: WP1: Study the molecular alterations in primary MM and environment cells in samples obtained from a large number of patients at treatment inclusion and relapse, using high throughput techniques. WP2: Implement in vitro and in vivo models of drug resistance to evaluate molecular and cellular mechanisms and compare their characteristics with drug resistant cells isolated from patients. Combined results of WP1 and WP2 will permit the identification of 10 prominent (altered) candidate genes involved in MM relapse. Changes in drug resistance, cell survival and proliferation will be assessed in WP2 by modulating the expression of the selected genes. WP3: Determine how cells from the niche alter their functions in the presence of drugs, and how drug-altered cells impact on MM cells during therapy. WP4: Screen chemical libraries for drugs active on generated sensitive cell lines, develop innovative inhibitors and provide proof of principle for a phase I/II trial'